Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 21 of 21 entries
View as:

A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06742879 Org: User:
Start: 05/01/24 End: 12/31/26 Due: 12/31/27

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05535673 Org: User:
Start: 09/02/22 End: 07/01/25 Due: 07/01/26

Management of Prostate Cancer in Central China

Phase: N/A Priority: Normal
NCT ID: NCT01614548 Org: User:
Start: 01/31/03 End: 12/31/11 Due: 12/31/12

Prognosis Factors in Patients With Primary Central Nervous System Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05167630 Org: User:
Start: 09/01/13 End: 12/15/21 Due: 12/15/22

Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

Phase: N/A Priority: Normal
NCT ID: NCT03914690 Org: User:
Start: 07/31/14 End: 07/31/19 Due: 07/31/20

Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03631862 Org: User:
Start: 09/01/18 End: 12/31/19 Due: 12/31/20

Systemic Hypothermia Improves Outcome of Hypoxic-Ischemic Encephalopathy

Phase: N/A Priority: Normal
NCT ID: NCT00817401 Org: User:
Start: 07/31/02 End: 06/30/08 Due: 06/30/09

Radiotherapy vs Observation for CRPC

Phase: N/A Priority: Normal
NCT ID: NCT01590498 Org: User:
Start: 05/31/12 End: 03/31/17 Due: 03/31/18

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03376958 Org: User:
Start: 01/01/17 End: 04/30/19 Due: 04/30/20

A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.

Phase: N/A Priority: Normal
NCT ID: NCT04999878 Org: User:
Start: 05/30/21 End: 06/30/24 Due: 06/30/25

Improving Wellbeing in Older Adults: The Impact of an Active Aging Education Program in Pakistan

Phase: N/A Priority: Normal
NCT ID: NCT05918289 Org: User:
Start: 08/15/22 End: 12/01/22 Due: 12/01/23

Impact of Baduanjin Exercise Combined With Rational Emotive Behavior Therapy on Sleep and Mood in Patients With Post-stroke Depression

Phase: N/A Priority: Normal
NCT ID: NCT06245850 Org: User:
Start: 06/20/21 End: 02/10/23 Due: 02/10/24

Effect of Educational Program on Parental Stress of Parents of Children With CHD

Phase: N/A Priority: Normal
NCT ID: NCT06172608 Org: User:
Start: 01/30/24 End: 04/30/24 Due: 04/30/25

Effectiveness and Economic Evaluation of Glass Ionomer Material Using as Dental Sealant

Phase: N/A Priority: Normal
NCT ID: NCT03034837 Org: User:
Start: 01/31/16 End: 06/30/18 Due: 06/30/19

Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06956092 Org: User:
Start: 05/30/25 End: 12/31/28 Due: 12/31/29

Recanalization and Stenting for Non-acute Veterbrobasilar Artery Occlusion

Phase: N/A Priority: Normal
NCT ID: NCT01632865 Org: User:
Start: 04/30/13 End: 12/31/15 Due: 12/31/16

Neurological Outcome After Erythropoietin Treatment for Neonatal Encephalopathy

Phase: N/A Priority: Normal
NCT ID: NCT00808704 Org: User:
Start: 08/31/03 End: 07/31/08 Due: 07/31/09

A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05506410 Org: User:
Start: 08/12/22 End: 12/30/26 Due: 12/30/27

Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06609304 Org: User:
Start: 09/30/24 End: 08/31/27 Due: 08/31/28

Dyadic Interventions to Boost Quality of Life Among Stroke Survivors and Care Partners in Pakistan.

Phase: N/A Priority: Normal
NCT ID: NCT06827093 Org: User:
Start: 10/01/21 End: 12/01/24 Due: 12/01/25

Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis

Phase: N/A Priority: Normal
NCT ID: NCT03919500 Org: User:
Start: 01/31/14 End: 04/30/19 Due: 04/30/20